Close Menu

NEW YORK – Interpace Diagnostics said today that it has closed on a $13 million convertible preferred stock investment by Ampersand Capital Partners. 

The Parsippany, New Jersey-based company noted that the investment is the second tranche of the $27 million convertible preferred stock financing provided by Ampersand to finance Interpace's acquisition of Cancer Genetics' biopharma business in July. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.